Comprehensive HIV and Harm Prevention Via Telehealth
Comprehensive HIV and Harm Prevention Via Telehealth: CHARIOT, a Randomized Controlled Trial
University of Miami
350 participants
Oct 7, 2024
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to test 2 different ways to offer medications to prevent human immunodeficiency virus (HIV), cure hepatitis C virus (HCV) (if applicable) and treat substance use disorder (if desired) in people who inject drugs.
Eligibility
Inclusion Criteria6
- age 18 or older
- able to speak English or Spanish
- willing and able to sign informed consent, provide locator information and medical records release
- non-reactive result on rapid HIV test
- use of SSP to exchange syringes 2 times in the past 3 months
- planning to stay in the area for 12 months
Exclusion Criteria8
- reactive HIV test
- currently on medications for opioid use disorder (MOUD) by urine drug screen
- currently on PrEP by self-report
- Principal or site investigator discretion
- currently in prison or jail
- current enrollment in Clinical Trials Network 121
- receipt of tele-harm reduction in previous 3 months
- signs or symptoms of acute HIV infection
Interventions
Comprehensive Tele-Harm Reduction is on-demand services including low-barrier access to PrEP, medications for substance use disorder and hepatitis C treatment. It includes mobile phlebotomy, peer harm reduction counseling, medication management, telehealth mental health/substance use disorder services-- all delivered via an syringe services program.
The community engagement team is comprised of peers and social workers and provides the wraparound support needed.The team will assist participants in scheduling appointments at community health clinics. The community engagement team provides active clinic referral- that is, a member of the team will accompany patients to the first clinic visit.
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05897099